StockNews.AI
HCM
StockNews.AI
181 days

HUTCHMED to Announce 2024 Final Results

1. HUTCHMED to announce 2024 results on March 19, 2025. 2. Conference call includes Q&A for analysts and investors. 3. HUTCHMED specializes in biopharmaceuticals for cancer and immunological diseases.

4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming results announcement may positively influence investor sentiment, akin to past earnings beats in the industry.

How important is it?

The earnings results are crucial for HCM's financial outlook and investor confidence.

Why Short Term?

Immediate impacts likely from the results announcement, similar to past financial events.

Related Companies

HCM
February 19, 2025 03:30 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will take place at 8:00 am EDT / 12:00 pm GMT / 8:00 pm HKT on Wednesday, March 19, 2025. In addition to the usual English webcast, there will also be a Chinese (Putonghua) webcast at 12:30 am GMT / 8:30 am HKT on Thursday, March 20, 2025 (8:30 pm EDT on Wednesday, March 19, 2025). Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event. About HUTCHMED HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn. CONTACTS Investor Enquiries+852 2121 8200 / ir@hutch-med.com  Media Enquiries FTI Consulting –+44 20 3727 1030 / HUTCHMED@fticonsulting.com     Ben Atwell / Alex Shaw     +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Brunswick – Zhou Yi+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com  Panmure LiberumNominated Advisor and Joint BrokerAtholl Tweedie / Freddy Crossley / Rupert Dearden+44 20 7886 2500  HSBCJoint BrokerSimon Alexander / Alina Vaskina / Arnav Kapoor+44 20 7991 8888  CavendishJoint BrokerGeoff Nash / Nigel Birks+44 20 7220 0500

Related News